Iovance Biotherapeutics names Noah Berkowitz chief medical officer

By Public Technologies
  • Iovance Biotherapeutics appointed Noah Berkowitz as chief medical officer, effective Sept. 30, 2026.
  • He previously served as chief medical officer at Arvinas Pharmaceuticals.
  • Berkowitz was senior vice president and therapeutic area head, hematology at Bristol Myers Squibb, overseeing hematology development and interim cell therapy programs.
  • Earlier roles included clinical development leadership at Novartis; he completed a medical oncology fellowship at the National Cancer Institute.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837591) on October 01, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk